This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk09: Welcome to the first quarter of fiscal year 2023 earnings conference call for Merit Medical Systems, Inc. At this time, all participants have been placed in listen-only mode. Please note that the conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Mr. Fred Lampropoulos, Merit Medical Systems founder, chairman, and chief executive officer.
spk08: Please go ahead, sir.
spk07: Thank you and welcome everyone to Merit Medical System's first quarter of fiscal year 2023 earnings conference call. I am joined on the call today by Rahul Parra, our Chief Financial Officer and Treasurer, and Brian Lloyd, our Chief Legal Officer and Corporate Secretary. Brian, would you mind taking us through the Safe Harbor Statements, please?
spk03: Thank you, Fred. I would like to remind everyone that this presentation contains forward-looking statements that receive safe harbor protection under federal securities laws. Although we believe these forward-looking statements are based on reasonable assumptions, they are subject to unknown risks and uncertainties. The realization of any of these risks or uncertainties as well as extraordinary events or transactions impacting our company could cause actual results to differ materially from those currently anticipated. In addition, any forward-looking statements represent our views only as of today, April 26, 2023, and should not be relied upon as representing our views as of any other date. We specifically disclaim any obligation to update such statements, except as required by applicable law. Please refer to the section entitled Cautionary Statement Regarding Forward-Looking Statements in today's presentation for important information regarding such statements. Please also refer to our most recent filings with the SEC for a discussion of factors that could cause actual results to differ from these forward-looking statements. Our financial statements are prepared in accordance with accounting principles which are generally accepted in the United States. However, we believe certain non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of our ongoing operations. and can be useful for period-over-period comparisons of such operations. This presentation also contains certain non-GAAP financial measures. A reconciliation of non-GAAP financial measures to the most directly comparable U.S. GAAP measures is included in today's press release and presentation furnished to the SEC under Form 8 . Please refer to the section of our presentation entitled Non-GAAP Financial Measures for important information regarding non-GAAP financial measures discussed on this call. Readers should consider non-GAAP financial measures in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. Please note that these calculations may not be comparable with similarly titled measures of other companies. Both today's press release and our presentation are available on the Investors page of our website. I will now turn the call back to Fred. Thank you, Brian.
spk07: Let me start with a brief agenda of what we will cover during our prepared remarks. I will start with an overview of our revenue results for the first quarter. After my opening remarks, Raul will provide you with a more in-depth review of our quarterly financial results and the formal financial guidance for 2023 that we updated in today's press release. as well as a summary of our balance sheet and financial condition as of March 31, 2023. We'll then open the call for questions. Now, beginning with a review of our first quarter revenue performance, we reported gap revenue of $297.6 million in the first quarter, up 8% year over year. Our total gap revenue growth was driven by 12% growth in the United States, and 3% growth in international sales. Our total revenue increased 9.8% year-over-year in the first quarter on an organic, constant currency basis, excluding the headwind to our GAAP revenue growth related to changes in exchange rates compared to the prior year period. Our first quarter revenue results were notably stronger than the growth expectations that we outlined in our fourth quarter call. Specifically, we shared our expectation for constant currency revenue growth in the range of 3 to 5% year over year in quarter one. Now, let me provide you with a more detailed review of our revenue results in the first quarter, beginning with a sales performance in each of our primary reportable product categories. Note, unless otherwise stated, all growth rates are approximated and are on a year-over-year and constant currency basis. We have included reconciliations from our GAAP reported results to the related non-GAAP item in our press release and presentation available on our website. First quarter total revenue growth was driven by 10% growth in our cardiovascular segment and 14% growth in our endoscopy segment. While constant currency growth exceeded the high end of our expectations in both segments, our cardiovascular segment drove nearly all of the revenue upside versus the high end of our expectations in quarter one. Sales of our peripheral intervention products increased 9%, representing the largest driver of total cardiovascular segment growth again this quarter. Within the PI product category, sales of both our drainage products and our access products increased 13% and together represented roughly 41% of total PI growth year over year. And sales of our radar localization biopsy and angiography products increased 10% and together represented roughly 39% of our total PI growth in quarter one. Of note, while the portfolio of products in our PI category continues to be the largest driver of growth in our cardiovascular segment, I believe it is important to appreciate the value of contributions to our total PI growth in recent years that come from our highly differentiated Scout radar localization product line. We have been pleased with the market response to our Scout mini reflector following the commercial launch in the first half of 2022. Continuing on with the discussion of our quarter one revenue growth drivers, sales of our OEM products increased 24% and were the second largest contributor to our total cardiovascular segment growth year over year. These results exceeded the high end of our growth expectations, which we attribute to continued improving demand from larger customers in multiple categories, including our EP and CRM kits and intervention products, which together increased more than 50% year-over-year in quarter one. Cardiac intervention products sales increased 7% in quarter one, with the three largest contributors to total CI growth coming from a 12% increase in sales of angiography products, and a 15% growth in sales of both our access products and our EPCRM products. Angiography products growth was driven by strong growth in sales of the inquire diagnostic guide wires. Access products growth was driven by high teens growth in sales of our prelude ideal and prelude radial sheets. EPCRM products growth was driven by strong demand for our SNAP and our heart span sheets, as well as our focus safeguard cool compression device, which is receiving positive market response following the commercial launch in August of last year. Sales of our custom procedural solutions or CPS products increased 6% which was notably better than the mid-to-high single-digit growth declines we expected in quarter one. This upside was driven primarily by stronger-than-expected demand for our CPS products from customers outside the U.S., specifically in Germany, the Middle East, and China, where sales increased in low double digits year-over-year in quarter one. Finally, sales in our endoscopy segment increased 14% which was modestly better than the high end of our growth expectations. While we are pleased to see the business return to growth in quarter one, as expected, endoscopy results continue to experience business disruption as we continue to navigate material shortages and work on qualifications for our new vendor. However, our guidance continues to assume improving trends as we move through the year, which we expect will result in mid-teens growth for our endoscopy business in 2023. Now turning to a brief summary of our sales performance on a geographic basis, our first quarter sales in the U.S. increased 11% year over year. Sales to U.S. customers came in roughly $5 million higher than the high end of our growth expectations and represented 62% of our total company constant currency growth this quarter. Our U.S. growth performance reflects continued strong execution and overall improving trends in the U.S. market, particularly in the month of March. International sales increased 9% year over year, which is strong performance in light of the challenging global macro environment in certain international markets. All three of our major regions posted growth above the high end of our expectation with sales in the EMEA, APAC, and rest of world regions increasing 17%, 2%, and 7%, respectively, year over year. While we are pleased to deliver international growth ahead of what our guidance has assumed as expected, our international growth was materially impacted by COVID-related headwinds in China, our largest OUS market. Sales in China declined in the high single digits year over year in quarter one, which exceeded our expectations due primarily to material improvements in trends in March. Excluding China, our total international growth was nearly 17% in quarter one. Now, while we were pleased with all three regions, which contribute to the stronger than expected growth, We saw the most upside versus expectations in the EMEA region where the reasons year-over-year growth was primarily driven by demand in France, Germany, the Middle East, and Spain. Excluding China, sales in APAC increased 21% fueled by mid-teens growth in Japan and strong contributions in growth from sales to customers in both Australia and Korea. And lastly, In our rest of world region, we delivered 7% growth year over year, driven by solid growth in Latin America, Brazil, and Mexico, partially offset by high single-digit declines in Canada compared to the prior year period. In summary, we couldn't be happier with a strong start to fiscal year 2023. We are certainly encouraged by the improvement growth trends in both the U.S. and international markets, but we recognize that the impressive results we delivered in quarter one are a direct result of our team's continued focus on executing our multi-year strategic plan. In a few moments, Raul will review our financial results for the quarter and the updated guidance which we announced in our press release this afternoon. I expect you will share my view that our financial performance in Q1 continues to demonstrate that the team's hard work and commitment to our foundations for growth program is paying off. Non-GAAP growth and operating margins of 50.1% and 16.1% respectively, and more than 20% growth year-over-year in both non-GAAP net income and non-GAAP earnings per share. Clearly, we are very, very proud of significant year-over-year improvements in profitability we delivered in the first quarter. Now that said, we're not losing focus and we know we have a lot of work yet to do this year. We have updated our 2023 financial guidance to reflect the better than expected financial results in the first quarter. Importantly, we remain confident in our team's ability to deliver continued progress in the three year and in year three, excuse me, of our Foundations for Growth program and the related financial targets for the three year period ending December 31, 2023, which called for our constant currency organic revenue growth to increase at a CAGR of at least 5%, non-GAAP operating margins of at least 18%, and cumulative free cash flow of more than $300 million. Now, with that said, let me turn the call over to Raul, who will take you through a detailed review of our first quarter financial results and our 2023 financial guidance, which we updated in today's press release.
spk04: Raul. Thank you, Fred. Given Fred's detailed discussion of our revenue results, I will begin with a review of our financial performance across the rest of the P&L. For the avoidance of doubt, unless otherwise noted, my commentary will focus on the company's non-GAAP results during the first quarter of fiscal year 2023. We have included reconciliations from our GAAP reported results to the related non-GAAP items in our press release and presentation available on our website. Gross profit increased approximately 13% year-over-year in the first quarter. Our gross margin for the first quarter was 50.1% compared to 47.7% in the prior year period, representing the highest first quarter gross margin in the company's history. The year-over-year increase in gross margin was primarily due to favorable changes in product mix improved obsolescence expense, freight and distribution, as well as other FFG-related efficiencies. As expected, our first quarter gross margins were impacted by the inflationary headwinds we are seeing in freight, logistics, labor, and raw materials. The 230 basis point increase in gross margins year over year exceeded the high end of the expectations we outlined on our Q4 call, which called for gross margins to increase 90 to 190 basis points year over year due primarily to fixed cost leverage on the better than expected sales performance in the period. Operating expenses increased 11% year over year in the first quarter. The year over year increase in operating expenses was driven by a 10% increase in SG&A expense and a 14% increase in R&D expense compared to the prior year period. Our operating expense performance in Q1 was better than expected. and reflects strong operating leverage due to our continued focus on expense management and prioritization of investments to support our future growth initiatives. Total operating income in the first quarter increased $7.7 million or 19% year-over-year to $48 million. Our operating margin for Q1 was 16.1% compared to 14.6% in the prior year period. The 150 basis point increase in operating margin was driven by a 230 basis point increase in our non-GAAP gross margin, offset partially by an 80 basis point increase in our non-GAAP OPEX margin compared to the prior year period. First quarter other expense net was 0.7 million compared to 0.9 million last year. The change in other expense net was primarily related to decreased expense from realized and unrealized foreign currency losses compared to the prior year period. partially offset by increased interest expense due to higher effective interest rates year over year. Note our other expense net line was roughly $1 million lower than what our guidance had assumed as a result of lower non-cash expense realized on foreign currency gain loss in the period. First quarter net income was $37.5 million, or $0.64 per share, compared to $30.4 million, or $0.53 per share, in the prior year period. We are pleased with our profitability performance in the first quarter, where we delivered 23% growth year-over-year in non-GAAP net income and 22% growth year-over-year in non-GAAP diluted earnings per share, exceeding the high end of our expectations. Turning to a review of our balance sheet and financial condition. As of March 31, 2023, we had cash and cash equivalents of $57.9 million, total debt obligations of $197.8 million, and available borrowing capacity of approximately $521 million compared to cash, cash equivalents of $58.4 million, total debt obligations of $198.2 million, and available borrowing capacity of approximately $523 million as of December 31st, 2022. Our net leverage ratio as of March 31st was 0.6 times on an adjusted basis. We generated $1.8 million of free cash flow in the first quarter Cash from operations increased 21% year-over-year in the first quarter, driven by the strong improvements in gap net income year-over-year, offset partially by an 11% increase year-over-year in the use of cash for working capital. In recent quarters, we have discussed our strategy to proactively invest in our inventory balances to build the requisite safety stock and ensure high customer service levels. Our free cash flow generation was also impacted by a 34% increase year-over-year and cash invested in capital expenditures. Turning to a review of our updated fiscal year 2023 financial guidance. We have included a table in our earnings press release which details the updated ranges for each of our formal financial guidance items and how those ranges compared to both prior guidance and the prior year period. We now expect GAAP net revenues growth of approximately six to seven percent year over year compared to four percent to five percent previously. The updated GAAP net revenue range now assumes a headwind from the changes in foreign currency exchange rates of approximately 3.5 to 4 million, representing a headwind to our forecasted GAAP growth rate of 30 to 40 basis points, compared to our prior guidance range, which assumed 10 to 11 million and 90 to 100 basis points, respectively. The GAAP net revenue guidance range now assumes net revenue growth of approximately 5 to 6 percent in our cardiovascular segment and net revenue growth of approximately 15 to 16% in our endoscopy segment. The increase in the low end of both these growth ranges reflects the stronger than expected revenues from the first quarter. Note, the midpoint of our 2023 constant currency sales growth expectations now assumes approximate 6% growth year-over-year in the U.S. and approximately 7% growth year-over-year in OUS markets. Both of these expectations are roughly 100 basis points higher than our prior guidance assumptions, which again reflect the stronger-than-expected revenue results from the first quarter. With respect to profitability guidance for 2023, we now expect GAAP NIC income in the range of approximately $100 million to $105 million unchanged from prior guidance, and GAAP diluted earnings per share of $1.71 to $1.79 versus $1.72 to $1.80 per diluted share previously, and non-GAAP net income in the range of approximately $166 million to $171 million, or $2.83 to $2.93 per diluted share, compared to $163 million to $168 million, or $2.80 to $2.89 per diluted share previously. For modeling purposes, our fiscal year 2023 financial guidance assumes non-GAAP gross margins in the range of approximately 50.7 to 51%, reflecting a 30 basis point increase at the low end versus prior guidance assumptions. Non-GAAP operating margins in a range of approximately 18% to 18.2%. GAAP and non-GAAP other expense of approximately $6.6 million and $6 million respectively, both of which reflect the $1 million lower expense versus guidance, which benefited our first quarter results that I discussed earlier. non-GAAP tax rate in the range of 21.5% to 22.5% versus approximately 21% previously, and diluted shares outstanding of approximately 58 million. We continue to expect CapEx in the range of 55 to 60 million and free cash flow of approximately 115 million. Lastly, we would like to provide additional transparency related to our growth and profitability expectations for the second quarter of 2023. Specifically, we expect our total revenue to increase in the range of approximately 4 to 6% year-over-year on a GAAP basis and up approximately 5 to 7% year-over-year on a constant currency basis. Note that the midpoint of our second quarter constant currency sales growth expectations assumes approximately 6% growth year-over-year in the U.S. and approximately 7% growth year-over-year in other U.S. markets. With respect to our profitability expectations for the second quarter, We expect to see non-GAAP gross margins increase in the range of 70 to 130 basis points year-over-year. We also expect to see non-GAAP operating margin in a range of down 20 basis points to down 60 basis points year-over-year. These margin expectations combined with higher interest expense year-over-year are expected to drive a year-over-year change in non-GAAP EPS in the range of flat year-over-year on the low end to up mid-single digits year-over-year on the high end of the range. That wraps up our prepared remarks. Operator, we would now like to open up the line for questions.
spk09: Thank you, sir. If you'd like to ask a question, please signal by pressing star 11 on your telephone keypad. If you're using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. We do ask that you limit yourself to one question and one follow-up. If you'd like to ask an additional question, we invite you to add yourself to the queue again by pressing star one one. One moment for our first question. And our first question comes from the line of Steve Lickman from Oppenheimer. Your line is open.
spk01: Thank you. Even guys. So really balanced strength here on the top line in the first quarter. I guess just for my question and my follow-up up front here, just touching on a couple of different areas. One, OEM, very solid again. If you talk about the drivers there and what you think is sort of the sustainable growth looking ahead for that segment. And then secondly, just in China, as we think geographically, given the strength in March, how are you feeling overall about the outlook for your business in China. Thanks.
spk07: Yeah, Steve, hey, thank you very much. Listen, I think the OEM issue really comes down to increased procedural growth rate. And to be very candid with you, reliability. I mean, people buy the product because we can deliver the product. So I think you take those two factors and those really spell out what the OEM opportunity is. In terms of sustainability, we're just going to stay within our forecast for the year. And if we see other things, we'll discuss that in further calls. But as you can see, the business is doing well there. And we're very, very pleased with the OEM. Raul, do you want to pick up the China question?
spk04: Yeah, look, I think I'll start off with just saying our international sales grew up 9% on a constant currency basis. Essentially, all three of our major regions posted above the high end of our expectations, which I think we were really excited about. And as expected, our OUS growth was impacted by the COVID-related headwinds in China, which we expected. I will call out that excluding China, our international sales were up nearly 17% on a constant currency basis. So I think we're excited how China came back in March. And we'll see how the rest of the year pans out. But excited about how our international sales did, you know, excluding that impact.
spk08: Great. Thanks, Fred and Roland. Thank you. One moment for our next question.
spk09: Our next question comes from the line of Jason Bedford from Raymond James. Your line is open.
spk05: Hi. Good afternoon and, excuse me, congrats on the success here. So, just a couple. On your comments on the strength in March, particularly in the U.S., Brad, you've been doing this for a few years. I'm just curious, why do you think March was so strong and kind of what are you seeing out there, either from a procedure standpoint or even a company-specific standpoint that maybe perhaps you're gaining a bit more share than others?
spk07: Yeah, listen, I think, Jason, as I mentioned in my previous, you know, comments on OEM, a lot of it's reliability and merit's ability to deliver while others are maybe still trying to catch up, and the procedural growth rate. So if you, I mean, you take those things, it's kind of consistent across the board. globally is our ability to do that, the vertical integration. Other things that we do as a business I think are playing well, have in the past, and we think will play well in the future as well.
spk05: Yeah, go ahead. I'm wondering, do you think there's kind of a catch-up of procedures out there? Is it an access situation here where hospital staffing has come down to allow hospitals to perform these more procedures? I'm just kind of curious from a macro perspective.
spk07: It's the question of the day. You know, we get this all the time. I was talking to another senior executive of a large medical device company, and they were still talking about the issues of staffing. We see some trends in staffing. On the other side of the coin, I think that you are seeing there's some pent-up demand out there, clearly. I think it's going to be out there for a while. So I think all of the factors, all of the macro factors, in my view, our view as a company, I think are paying in merit's favor.
spk05: Okay. Just on gross margin, it was clearly quite strong in the first quarter. You lifted the gross margin guide, but the operating margin assumption didn't really change for the year. So I'm just curious as to where the incremental reinvestment is going.
spk07: Yeah, I'm going to pick up the front end and let Raul talk in the back. Listen, we talked about previous calls about sales meetings. We talked about trade shows and those things. And we talked about making those investments in our previous phone calls saying they were coming as this COVID situation unwrapped. And in fact, that's exactly, you know, we have a couple of trade shows this week. So it really is trade shows and sales meetings. And just briefly on the sales meetings, I attended them, and it's just nothing like getting the team together, talking about their successes, their opportunities, and the camaraderie that comes with all of that is important in any type of organization. I've seen it through my military career and my business career. Raul, do you want to pick up the gross margin part?
spk04: Yeah, look, I think on the gross margin, you know, clearly the strong sales, you know, allowed us to better cover our fixed coverage, you know, so that helped the gross margin kind of exceed, you know, where we thought we'd end. Additionally, you know, on the operating margin targets, look, I think, you know, one of the things that I'll call out, you know, it's kind of foundations for growth, right? There is a level of investment that we're making in the business, specifically as this gross margin comes in. We've been You know, we've continued to talk about that, about that, you know, prudent investment in growth initiatives. And so I think it's really just about balancing, Jason, the growth that we're seeing, the profitability in our gross margin that we're seeing, and then just making sure that we find the right balance between delivering, you know, increased profitability and just making sure that we have, you know, continued success on the growth side. Okay. Thank you.
spk09: One moment for our next question. And our next question comes from the line of Mike Mattson from Needham. Your line is open.
spk12: Yeah, good afternoon. Thanks for taking my questions. I guess I'll start with, you know, the gross margin was obviously really strong and you called out product mix. I was wondering if you could maybe just talk about, you know, what you're seeing there, kind of the categories that are higher margin and maybe growing faster versus the ones that are lower margin and maybe growing slower, driving that mixed benefit.
spk04: Yes, you know, well, I'll call out a couple things first, right? We saw improved, you know, obsolescence expense. Obviously, the freight and distribution as we shipped from ocean, sorry, from air to ocean is helping. We also have some related FFG initiatives that are flowing through that are helping. On the product mix side, we continue to see growth in our Ciana product line, in our peripheral intervention areas. OEM was a strong player, too, which has increased gross margins. So just kind of a mix of different things, Mike.
spk07: Can I add something, Raul, if I could just? I think with our chief commercial officer and aligning all of our global initiatives and support is also something that just overall plays well for the business. That's Joe Wright and his team. And I think it's a much more cohesive and effective unit in the commercial side that drives business. Because remember, we're all tied – everybody in this company is tied to margins and results. And when you line all that up, it's just really interesting to see what happens.
spk12: Yeah, okay. So it's more of a – this is more of a kind of a deliberate effort on your part as opposed to just kind of something that happened. You're deliberately powering this product. Yeah, there are margins.
spk07: Yeah, let me just tell you, everything out here is deliberate. You better get some deliberate. They've got somebody in their office. I've got them in mine. I'm in theirs. It's very deliberate.
spk04: Yeah, and just lastly, Mike, I mean, I think, you know, our guidance, you know, kind of previewed, you know, the gross margin that we were expecting, right? So, you know, slightly ahead of what we thought, you know, just from a fixed cost leverage in Q1, but, you know, generally, you know, within the guidance that we've given. Okay.
spk12: Okay. Thanks. And then kind of a, kind of a related question, I guess, just, I feel like when you started the foundations for growth program, I think one of the things you talked about was some skew rationalization, product rationalization of some kind of lower margin categories and things like that. And, you know, I just wanted to get an update there. Is that sort of been accomplished or, you know, and is that maybe having an effect on, or has that had an effect on gross margins?
spk04: So, yeah, yeah. Look at the, Um, skew rationalization is a program. It's quite frankly, a multi-year program. And if we're successful, you shouldn't notice other than gross margin accretion. Um, you know, we've gotten rid of some pack businesses, you know, in Australia, some pack business in, in, um, in Ireland, um, in Europe, in Europe also, that'll be, you know, that'll be kind of fully gone here, you know, by, by mid year. So generally it is one of the initiatives that we continue to work on. And again, it's a multi-year approach. Most of it is kind of, we've got, you know, better, higher quality and higher gross margin products that we want to replace it with.
spk07: And, you know, Mike, some of it comes in efficiency too, where we might be, we have a catheter that we're selling hundreds of a month and it might be five centimeters longer or shorter. And then we have something that we sell tens of thousands a month and we move them over. So that's Q rationalization comes not only just in low products, but also and margins there, but in the efficiency of manufacturing.
spk04: Low runners.
spk07: Yeah, low runners. I think we keep our customers happy. They're thrilled that we talk with them and work this out and have this transition. So that's why you have to do this in a sequence, and it has to be well-disciplined. You want to keep your customers happy instead of someone, and I've seen this happen with other players. They just go out and just knock something off with no input. this or that, and they upset their customers. It's just not a smart way to do business. That's what we've tried to do.
spk08: Okay, great. Thank you. One moment for our next question. Our next question comes from the line of James Sedoti from Sedoti.
spk09: Your line is open.
spk06: Hi, good afternoon, and thanks for taking the questions. You know, it There's been a couple of years I looked back where Q1 exceeded Q4, but it isn't very common, especially when you have a slowdown in China due to COVID. So it's especially impressive this year. Were there any one-time things in the quarter or is it just the procedures are starting to come back?
spk07: Listen, I think it's execution. I think it's the coordination of selling organizations throughout the world and messaging. And I think part of it is increased procedure growth rates that we talked about, particularly later in the first quarter. We're seeing those kinds of things, Jim, but nothing that I'm aware of, Raul. I'm not aware of any one-time anythings.
spk04: No, I mean, our guidance is built on things kind of opening up over the year. So we'll see, you know, March is one month and, you know, the quarter is one month. We'll see how the rest of the stuff, you know. But we're excited about how things have trended so far.
spk06: And is pricing been a factor? You know, I know you have thousands of products, so it's hard to say what your average price increase is. But how much of the growth would you estimate came from pricing?
spk04: That's a great question, Jim. But, you know, we're not going to, you know, discuss that on the call. Or we just don't, we actually don't disclose that publicly. But I will say that most of our growth continues to be volume and pricing is a benefit that we're getting and, you know, continue to expect to get.
spk06: Okay. And then on the expense on R&D up, you know, three or four million in the quarter, you know, what, is that due to trials or what's going into that?
spk04: Yeah, trials and just making sure that we invest, you know, continue to invest in the business. Again, I think what we're trying to do is make sure that we're prudent about, you know, the way we deliver profits, but also continue to invest in the business.
spk06: Okay, and then the last one from the inventory, you noted how, you know, that increased from the beginning of the year. Is that all safety stock? Is there any anticipation of... continued strong growth in the rest of the year and, you know, what can we read out of that?
spk04: Yeah, look, a large part of it is really kind of our strategy just to make sure that we can maintain the customer service levels that we, you know, that our customers expect of us. We've been in a good position that we've been able to deliver product and we want to continue to be able to do that. Secondarily, we've got, you know, the shift from air to ocean, which does require a you know, as it, as in the lag. And then also just, you know, some of the site consolidations and product line transfers that we have. So it's a combination of a few things, but mostly it's really just about making sure that we can meet our customers' needs.
spk06: Do you think you'll see a similar increase in the second quarter, or do you think you're, you know, you've already built it up to the point where it's going to be more of a slower increase?
spk04: You know, we don't give intra-quarter, you know, or intra-month, you know, guidance on free cash flow just because of the timing of things. We haven't changed our free cash flow target of $115 million. So I'm going to leave it at that, Jim, if you're okay with that.
spk06: Yep. All right. Got it. Thank you. One moment for our next question.
spk09: Our next question will come from the line of Jason Bednar from Piper Sandler. Your line is open.
spk02: Hey, good afternoon. Thanks for taking the questions, and congrats, Dan. A really nice start to the year, guys. Thanks. Apologies in advance, man. This has been covered. I've been hopping in between a couple of calls here. Raul, just to start with you, really maybe just trying to understand the components of the full year guide at the revenue line. We've got one queue in the books. We have kind of the two-queue formal or informal guidance, however you want to think about it. That's out there now. I think when I put this together, and again, I still need to work through some of the elements of the model, but I think this implies a slight decel in the growth in the second half of the year. I think the comps are actually a bit easier, though, in the second half. Pricing probably is getting a little bit better. China's probably better in the second half than the first half. So maybe just help with the sequencing as we think through the factors influencing the cadence of that organic growth.
spk04: Yeah, we really didn't change any of the assumptions from Q2 to Q4. You know, it's really what you're seeing from a guidance perspective or the updated guidance is a strong Q1. Again, what we saw is, you know, January, February in line with our expectations and then a very strong March. And we don't want to go out and get ahead of ourselves, Jason. I think what we want to see is, you know, let's see if this one month turns into, you know, three months and then, you know, six months and then a full year. So I think that's where we're at. Again, not much has changed in the back half.
spk02: Okay. Yeah, fair enough. And then on the free cash flow outlook, maybe building on a little bit of Jim's question there previously, but how do we think about the cadence of that $115 million coming through, working towards moving all the way back to ocean versus air freight? And then how should we think about the capital allocation here this year? Is it still the working assumption you just continue to pay down debt?
spk04: Yeah, we'll continue to pay down debt. And again, I think $115 million is still our target for the year. We did talk about some timing-based items in our Q4 call just a couple months ago related to Q1. But we don't give intra-quarter information on free cash flow just because it's so tricky on a timing base. But look, we haven't changed our target yet. So I think hopefully that gives you the confidence that we see in here.
spk02: Yeah, definitely. Okay. And then, Fred or Raul, it seems like you're clearly picking up share here in the market, have been for multiple years now. But maybe talk about the competitive landscape as it stands today as we look out across your key geographies, the U.S., Europe, and China. Any shifts or changes that are worth calling out?
spk07: You know, I think, Jason, that the real factor is our ability to provide product in the reliability. That's where this comes from. And that goes back to vertical integration, all the things we've talked about for a very long time. It's really the core of Merit's business is the opportunity. You've heard what I will say several times on this call is getting the product to customers and the reliability. Everybody's out there fighting for the same healthcare dollar. And the question is, who does it better? And our goal is to just continually improve to meet that need. And also, as was pointed out, to invest in the business for new products that make it easier for physicians and technicians to be able to do their job. So it's kind of the same thing we've been doing for a long time, but with maybe a little bit more of a sharpened focus.
spk02: All right. Well, congrats again.
spk07: Thank you very much.
spk09: One moment for our next question. Our next question comes from the line of Michael Petoskey from Barrington Research. Your line is open.
spk11: Good evening, guys. I guess slightly beating the dead horse, but I just want to ask, the free cash flow generation in the first quarter, and I understand certainly Q1 is always going to be the lowest, but did that come in a little soft even relative to internal, or was that actually relatively in line?
spk04: Again, Mike, I think we talked about it being, you know, soft in Q1. You know, as a matter of fact, I believe you asked the question, right? You know, hey, you know, what's the cadence of free cash flow? And again, I always call out Q1 because it is lighter than what we expect. And so I'll just leave it at that. You know, again, we haven't changed our free cash flow target for the year. So hopefully that gives you some confidence of where we're at.
spk11: Okay, fair enough. And I didn't catch the commentary about China and March. It sounded like you said it got better, but did you quantify that or just essentially say, hey, China got better in March?
spk04: Yeah, no quantification. Just China got better, right? It exceeded our expectations. And, you know, so hopefully that'll continue.
spk11: And I guess, Fred, in terms of what you guys are seeing out there in terms of assets, I mean, are you seeing more? What kind of valuations are you seeing with interest rates, where they are? I mean, how has that changed the landscape? I mean, and I guess you're thinking about assets. If you could just talk about that, thanks.
spk07: Yeah, listen, I think it's changed substantially, not enough necessarily. to what we'd like to see. I think there are a lot of very high expectations out there. We see a lot of things coming across our desk. We look at them. But again, the best way we put it, Mike, is that we are looking for things that fit our sales channels, things that are complementary to our foundations for growth, and the profitability, all the things that we talked about. We are seeing things, though, loosen up. As you know, and we've said before on previous calls, things were just simply too expensive. And I think that's, you know, without getting too prophetic here, I mean, we talked about that, is that it just didn't make sense to us to be, you know, in these prices. So things are loosening. There's more availability. A lot of them are still those startups or those companies that are not making money. That's not of much interest, but at the same time, there are assets starting to show up, and we'll look at them and see if they meet our criteria.
spk04: Roland? Yeah, I'll just add that, you know, I mean, I think if you look at our growth, you know, we continue to display pretty strong growth. And so I think we can continue to exercise patience. And we don't have to do anything because we don't, you know, we're not suffering from a growth.
spk07: It's a really good point, Merle. We don't have to do anything, but we can be opportunistic. That's right.
spk11: Just real quick, let me sneak one more in. One question that I've gotten increasingly the last few months regarding merit, and I think this is truly a compliment to you guys in how you've executed two-thirds of the way in or a little more than two-thirds of the way in on foundations for growth. I've had multiple questions from investors about Do I think that Merritt will do some other multi-year sort of target plan after 23 is over? I understand you're super focused, hyper focused on executing what you've put out there, but do you have any comment on whether it's likely you'll do something similar going forward? Thanks.
spk07: Yeah, I can tell you that Raul and I would do a duet on this, and if some You know, exactly like that. So give them your part of the duet there, Rahul, because I have the same answer.
spk04: Yeah, I mean, I think the way to look at it is, the way we look at it internally is we don't want to be that wide-open receiver that drops the ball at the one-yard line. So we want to, I understand everybody's, you know, focus of, you know, past 23, but we are just hyper-focused on making sure we cross that finish line, we score that touchdown, and that's where we're at.
spk07: And Mike, we are all aligned to that goal. Every single person in this company is aligned on that goal in a compensation, goals, company, individual, departments, and so on and so forth. That's eye on the ball until, and they talk about football. I'm a baseball guy. I mean, we got to get the last out in the ninth inning and then you win the World Series. You don't win it in the sixth inning. So I guess it would be, If you had four quarters, 12, it's the 11th inning. We're playing extra innings. So we just want to finish it up. And that's what you'll hear us say. It's very consistent. And then we'll talk about where we go from there.
spk11: Fred, the only comment I have on that is, given the state of the Red Sox, I'm surprised you're still a baseball fan. But good luck. Thank you.
spk05: You know, that's a cheap shot.
spk07: And not only that, I've got an Orioles guy sitting in the room here with me. They won 6-2 today. I'm really hurt. I'm very, very hurt over that comment.
spk11: Sorry, Fred. I'm sorry.
spk07: Yeah, especially a guy from Chicago. Come on. All right.
spk05: Thanks, Mike.
spk09: One moment for our next question. Our next question comes from William Plovonik from Canaccord. Your line is open.
spk10: Great. Thanks for taking my questions. I just have two. One is, you know, looking at the business today and understanding, you know, everything you've done, what do you think peak operating margins could be for this business eventually? And then my second question, I'll give it and then I'll go on mute, is, you know, one of the questions that I get from investors is, you know, Fred, you've built this company since the 80s. You've done a phenomenal job. You know, how should we think about, you know, is there some point which you step down? Is there succession planning or how do we think about that? Thanks for taking my question.
spk07: Yeah, you're welcome. Let me hit that, the last one there. Listen, we have a formal program. We will have an announcement by this year in the second half of the year that lays it out in a public release to everybody. You shouldn't read into that that that's the end. I want to make sure that's clear, but it'll spell out the succession program that's being run by our ESG and our comp committee. So that will come out formally, and that'll answer your question. In terms of peak performance, we just don't talk about that. Remember that goal line, Bill? It's the home plate, the goal line, the net. That's it. Touchdown. Touchdown. Yeah, we'll cross that bridge when it's time to cross. It's not at this point, and we want to stay consistent.
spk08: And there was silence.
spk09: All right. Thank you. And I'm not showing any further questions in the queue. I'd like to turn the call back over to Fred for any closing remarks.
spk07: Well, ladies and gentlemen, thank you very much for your time. There's a lot of calls out there. I know you're busy, so we'll Just again, thank you once again. We appreciate it. We'll sign off now from Salt Lake City. Raul and I will be available for the next few hours to answer questions, and we'll talk to you then. Thank you very much, and good evening. And that does conclude our conference call for today. Thank you for your participation. Everyone have a great day.
Disclaimer